Development and validation of a nomogram to predict recurrence and melanoma-specific mortality in patients with negative sentinel lymph nodes
- PMID: 30307046
- PMCID: PMC6585628
- DOI: 10.1002/bjs.10995
Development and validation of a nomogram to predict recurrence and melanoma-specific mortality in patients with negative sentinel lymph nodes
Abstract
Background: Patients with melanoma and negative sentinel nodes (SNs) have varying outcomes, dependent on several prognostic factors. Considering all these factors in a prediction model might aid in identifying patients who could benefit from a personalized treatment strategy. The objective was to construct and validate a nomogram for recurrence and melanoma-specific mortality (MSM) in patients with melanoma and negative SNs.
Methods: A total of 3220 patients with negative SNs were identified from a cohort of 4124 patients from four EORTC Melanoma Group centres who underwent sentinel lymph node biopsy. Prognostic factors for recurrence and MSM were studied with Cox regression analysis. Significant factors were incorporated in the models. Performance was assessed by discrimination (c-index) and calibration in cross-validation across the four centres. A nomogram was developed for graphical presentation.
Results: There were 3180 eligible patients. The final prediction model for recurrence and the calibrated model for MSM included three independent prognostic factors: ulceration, anatomical location and Breslow thickness. The c-index was 0·74 for recurrence and 0·76 for the calibrated MSM model. Cross-validation across the four centres showed reasonable model performance. A nomogram was developed based on these models. One-third of the patients had a 5-year recurrence probability of 8·2 per cent or less, and one-third had a recurrence probability of 23·0 per cent or more.
Conclusion: A nomogram for predicting recurrence and MSM in patients with melanoma and negative SNs was constructed and validated. It could provide personalized estimates useful for tailoring surveillance strategies (reduce or increase intensity), and selection of patients for adjuvant therapy or clinical trials.
© 2018 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd.
Figures

Similar articles
-
External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma.Br J Surg. 2019 Sep;106(10):1319-1326. doi: 10.1002/bjs.11262. Epub 2019 Jul 16. Br J Surg. 2019. PMID: 31310333 Free PMC article.
-
The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection.Eur J Cancer. 2020 Jul;134:9-18. doi: 10.1016/j.ejca.2020.04.022. Epub 2020 May 23. Eur J Cancer. 2020. PMID: 32454396
-
Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data.Br J Surg. 2021 May 27;108(5):550-553. doi: 10.1002/bjs.11946. Br J Surg. 2021. PMID: 34043770
-
Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.Recent Results Cancer Res. 2000;157:178-89. doi: 10.1007/978-3-642-57151-0_15. Recent Results Cancer Res. 2000. PMID: 10857171 Review.
-
Tissue prognostic biomarkers in primary cutaneous melanoma.Virchows Arch. 2014 Mar;464(3):265-81. doi: 10.1007/s00428-013-1526-x. Epub 2014 Feb 1. Virchows Arch. 2014. PMID: 24487785 Review.
Cited by
-
Establishment and validation of a nomogram for predicting immune-related prognostic features in trunk melanoma-specific death.Ann Transl Med. 2022 Dec;10(24):1371. doi: 10.21037/atm-22-6045. Ann Transl Med. 2022. PMID: 36660695 Free PMC article.
-
External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma.Br J Surg. 2019 Sep;106(10):1319-1326. doi: 10.1002/bjs.11262. Epub 2019 Jul 16. Br J Surg. 2019. PMID: 31310333 Free PMC article.
-
Predictive accuracy of risk prediction models for recurrence, metastasis and survival for early-stage cutaneous melanoma: a systematic review.BMJ Open. 2023 Sep 28;13(9):e073306. doi: 10.1136/bmjopen-2023-073306. BMJ Open. 2023. PMID: 37770261 Free PMC article.
-
The Dutch Early-Stage Melanoma (D-ESMEL) study: a discovery set and validation cohort to predict the absolute risk of distant metastases in stage I/II cutaneous melanoma.Eur J Epidemiol. 2025 Jan;40(1):27-42. doi: 10.1007/s10654-024-01188-4. Epub 2025 Jan 9. Eur J Epidemiol. 2025. PMID: 39786688 Free PMC article.
-
Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I-II Melanoma Patients at Risk of Disease Relapse.Cancers (Basel). 2022 Jun 9;14(12):2854. doi: 10.3390/cancers14122854. Cancers (Basel). 2022. PMID: 35740520 Free PMC article.
References
-
- Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK et al Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392–399. - PubMed
-
- Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N et al Prognostic factors analysis of 17 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622–3634. - PubMed
-
- Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C et al Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG‐SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 2016; 17: 757–767. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases